Valvular & structural heart disease
Continued non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists during transcatheter aortic valve implantation
Main findingResult — go to the resultOdds ratio 0.68 95% CI 0.43–1.07Authors' conclusion
Continued NOAC compared with continued VKA during TAVI led to comparable outcomes with regard to the composite outcome measure indicating that continued OAC with both drugs is feasible.
Study context
- Population
- Consecutive patients on oral anticoagulation (OAC) undergoing transfemoral transcatheter aortic valve implantation (TAVI) at five European centres
- Participants
- 584 patients
- Exposure
- Continued NOAC vs continued vitamin K antagonist (VKA) during TAVI
- NOACn = 290
- VKAn = 294reference
- Outcome
- Composite of:
- Major/life-threatening bleeding
- Stroke
- All-cause mortality
- Follow-up
- 30 days
Methodological detailsmulticentre, propensity-score matched
- Multicentre
- Propensity-score matched
Main finding
As reported in the abstract
Odds ratio
0.68
95% CI 0.43–1.07
P = 0.092
Events by group
NOAC vs VKA
OR 0.68 (95% CI 0.43–1.07); P = 0.092
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| All-cause mortality · 1 yearMultivariate Cox regression · propensity score-matched cohort revealed similar results | 0.61 (0.37–0.98) | P = 0.043 | |
| 0.20.5125Hazard ratio (log scale) |
Safety
Major/life-threatening bleeding · 30 days
- Not different between groups
- OR 0.87, 95% CI: 0.52-1.47; p=0.606
Stroke · 30 days
- Not different between groups
- OR 1.02, 95% CI: 0.29-3.59; p=0.974
Original publication
Continued non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists during transcatheter aortic valve implantation. EuroIntervention. Published 6 February 2023. doi:10.
Summarised from the published abstract; every number is checked against it